Skip to main content

Table 1 Parameters of the univariate analysis of clinicopathological factors

From: Epstein-Barr virus infection and clinical outcome in breast cancer patients correlate with immune cell TNF-α/IFN-γ response

Explicative variables

Relative risk (95% CI)

p-value

Tumor size

2.04 (1.412–2.95)

0.00015

Grade 1

-

-

Grade 2

1.38 (0.30–6.30)

0.679

Grade 3

2.92 (0.63–13.54)

0.171

Relapse

14.95 (5.67–39.44)

<0.0001

EBV-T +

0.795 (0.291–2.173)

0.65

EBV-P +

1.05 (0.44–2.51)

0.91

ER/PR positive

0.48 (0.19–1.20)

0.116

HER-2 positive

2.71 (0.795–9.21)

0.111

Lymph node invasion

6.32 (2.31–17.3)

0.0003

Anti-ZEBRA antibody titration

4,63 (1.75–12.23)

0.002

  1. EBV: Epstein-Barr virus; T+: detected in tumors; P+: detected in PBMCs; ER/PR: estrogen/progesterone receptor; HER-2: human epidermal growth factor receptor 2; anti-ZEBRA: antibodies to BamH1 Z Epstein-Barr replication activator.